Stamford-based Olympus Partners is pleased to announce that it has acquired Holopack International Corp. from The Hansen Corporate Group. Holopack International, headquartered in Columbia, S.C., will immediately change its name to The Ritedose Corporation (TRC).

TRC is a leading contract blow-fill-seal (BFS) manufacturer in the United States. In the BFS process, a plastic container is molded, filled and sealed in a continuous sterile process.

TRC manufactures a variety of prescription pharmaceuticals targeted primarily at the respiratory market. These products are primarily administered through nebulizers. In addition, TRC uses RiteDose, its patented unit dose technology, to package OTC pharmaceuticals for major brands.

Rob Morris, Managing Partner of Olympus Partners, commented, "We are excited about investing beside TRC's management to continue rapidly expanding its business with existing and new customers and maintaining TRC's position at the cutting edge of the BFS technology."

Founded in 1988, Olympus Partners is a Stamford, Conn.-based private equity firm focused on providing equity capital for middle market management buyouts and for companies needing capital for expansion. Olympus is an active, long-term investor across a broad range of industries, including healthcare services, financial services, consumer products and business services. Olympus manages in excess of $3 billion on behalf of corporate pension funds, endowment funds and state-sponsored retirement programs.

The Olympus team included Jim Conroy, Evan Eason, Jason Miller and Arjun Bhattacherjee. Olympus was represented by John Schoenfeld, James Faley and Rob Kiburz of Kirkland & Ellis LLP.

Graham Schindler of Houlihan Lokey advised the seller on the transaction.